Paper40445239
Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells.
Bopp AR and 10 others. Cancer Immunol Immunother, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. Papers, record 40445239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40445239
- Cell line
- CAL-27113 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells.
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pyrimidines | Major topic |
| Agammaglobulinaemia Tyrosine Kinase | Major topic |
| Pyrazoles | Major topic |
| Squamous Cell Carcinoma of Head and Neck | Major topic |
| Head and Neck Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| T-Lymphocytes | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Piperidines | |
| Animals | |
| Adenine | |
| Mice | |
| Humans | |
| Tumor Microenvironment | |
| Cell Line, Tumor | |
| Xenograft Model Antitumor Assays | |
| Lymphocytes, Tumor-Infiltrating | |
| Tyrosine Kinase Inhibitors |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| DP1 DA054344 | NIDA NIH HHS | United States | DP1DA054344 | PubMed and NIH | NIH RePORTER |
| R01 DE033906 | NIDCR NIH HHS | United States | R01DE033906 | PubMed | NIH RePORTER |
| RSG-19079-01-TBG | American Cancer Society | PubMed | PubMed | ||
| DP1DA054344 | NIH HHS | United States | DP1DA054344 | PubMed and NIH | NIH RePORTER |
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29709262 | New Therapies in Head and Neck Cancer. | Trends Cancer | 2018 | https://conductscience.org/library/papers/29709262 | PubMed |
| 2 | 33243986 | Head and neck squamous cell carcinoma. | Nat Rev Dis Primers | 2020 | https://conductscience.org/library/papers/33243986 | PubMed |
| 3 | 31307547 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31307547 | PubMed |
| 4 | 29355614 | Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. | Semin Cancer Biol | 2018 | https://conductscience.org/library/papers/29355614 | PubMed |
| 5 | 33477635 | Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33477635 | PubMed |
| 6 | 34307353 | Bruton's Tyrosine Kinase and Its Isoforms in Cancer. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34307353 | PubMed |
| 7 | 31764119 | Bruton Tyrosine Kinase Inhibitors: Present and Future. | Cancer J | 2019 | https://conductscience.org/library/papers/31764119 | PubMed |
| 8 | 33122850 | Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. | Leukemia | 2021 | https://conductscience.org/library/papers/33122850 | PubMed |
| 9 | 35456016 | Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions. | Cells | 2022 | https://conductscience.org/library/papers/35456016 | PubMed |
| 10 | 29455639 | Role of Bruton's tyrosine kinase in B cells and malignancies. | Mol Cancer | 2018 | https://conductscience.org/library/papers/29455639 | PubMed |
| 11 | 24658273 | Targeting Bruton's tyrosine kinase in B cell malignancies. | Nat Rev Cancer | 2014 | https://conductscience.org/library/papers/24658273 | PubMed |
| 12 | 26383180 | Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. | Cancer Biol Ther | 2015 | https://conductscience.org/library/papers/26383180 | PubMed |
| 13 | 26036311 | Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. | Oncotarget | 2015 | https://conductscience.org/library/papers/26036311 | PubMed |
| 14 | 36593070 | Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/36593070 | PubMed |
| 15 | 32025027 | Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. | Br J Cancer | 2020 | https://conductscience.org/library/papers/32025027 | PubMed |
| 16 | 23913792 | A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. | Genes Chromosomes Cancer | 2013 | https://conductscience.org/library/papers/23913792 | PubMed |
| 17 | 31238520 | Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31238520 | PubMed |
| 18 | 34164404 | p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34164404 | PubMed |
| 19 | 30733667 | Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype. | Front Mol Neurosci | 2019 | https://conductscience.org/library/papers/30733667 | PubMed |
| 20 | 31200752 | p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31200752 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42612021 | Myeloid-derived MIF is a central regulator of MDSC-driven T-cell dysfunction in head and neck squamous cell carcinoma. | Oncoimmunology | 2026 | https://conductscience.org/library/papers/42612021 | PubMed |
| 41818928 | Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma. | Oral Oncol | 2026 | https://conductscience.org/library/papers/41818928 | PubMed |
| 41598706 | Diagnostic, Prognostic, and Predictive Molecular Biomarkers in Head and Neck Squamous Cell Carcinoma: A Comprehensive Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/41598706 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40445239
GET https://conductscience.org/api/papers/v1/40445239/references?page=2